Announcements Trials
Browse Landscape

Phase

Phase 2 2Phase 1 1

Status

Terminated 3Completed 1

Sponsor Class

OTHER 2INDUSTRY 1

Study Type

Interventional 3

Sponsor

Cancer Type

Gastrointestinal 3

Conditions

Pancreatic Neoplasms 2Colorectal Neoplasms 1

Interventions

Fluorouracil 145Gemcitabine 141Oxaliplatin 135Capecitabine 133Leucovorin 107Irinotecan 99Bevacizumab 92Cetuximab 69Cisplatin 67pembrolizumab 61Radiotherapy 60Nivolumab 41130-nm albumin-bound paclitaxel 41Sorafenib 39Docetaxel 34Albumin-Bound Paclitaxel 31Radiosurgery 28Paclitaxel 27Surgical Procedures, Operative 25regorafenib 24Erlotinib Hydrochloride 23Panitumumab 22Cyclophosphamide 21Celecoxib 20Trastuzumab 19Radiation 18Neoadjuvant Therapy 18IFL protocol 18atezolizumab 17Carboplatin 17

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Terminated × NIS-793 × Gastrointestinal × Clear all
NCT05417386 2025-11-18

FOLFIRINOX + NIS793 in Pancreatic Cancer

Massachusetts General Hospital

Phase 1 Terminated
4 enrolled
Gastrointestinal

Pancreatic Neoplasms

NCT04952753 2025-03-26

daNIS-3

Novartis

Phase 2 Terminated
204 enrolled
Gastrointestinal

Colorectal Neoplasms

NCT05546411 2024-12-17

A Trial of NIS793 With FOLFIRINOX in Pancreatic Cancer

Dana-Farber Cancer Institute

Phase 2 Terminated
8 enrolled 11 charts
Gastrointestinal

Pancreatic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡